Nature Reviews Immunology (2020) https://doi.org/10.1038/s41577-020-0331-4 Published online 06 May 2020

In the originally published article, the imprecise wording of a sentence implied that IL-6 blockade had been approved by the FDA for treatment of COVID-19. This has now been corrected in the HTML and PDF versions of the article to clarify that the FDA had, at the time of writing, only approved trials of IL-6 blockade in patients with COVID-19.